Positive news just came out from Longeveron (Nasdaq: LGVN) which is soaring 44% on over 45 million shares today. Lomecel-B, a potential candidate to combat Alzheimer patients, has been under clinical trial. In phase 2 results show support for further study on Lomecel-B to slow the cognitive decline of the patients. So far the first patient has participated in the trial.
LGVN Stock may fall tomorrow for the sake of correction
Right now the stock is trading near $10 while it has negative EPS which can impact negatively long-term shareholders. Anyway day traders will start selling or shorting LGVN stock to make at least $20 for tomorrow. Therefore, holding the stock is meaningless unless Longeveron announces the next positive update from clinical trials tomorrow.